Germany’s patent court has invalidated a patent that was the basis of a patent violation lawsuit CureVac (CVAC) filed against BioNTech (BNTX), Reuters reports. This ruling is a blow to CureVac’s claims for a share in COVID-19 vaccine revenues.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BNTX:
- BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
- Barron’s 10 Favorite Stocks for 2024 include Alibaba, Alphabet, Chevron
- BioNTech price target raised by $1 at Morgan Stanley, here’s why
- BioNTech to Inaugurate First African Site on December 18, 2023
- BioNTech downgraded to Underweight from Neutral at JPMorgan